Website intended for a NZ health professional readership
How effective is taxane-based chemohormonal therapy for newly diagnosed, metastatic, hormone-sensitive prostate cancer?
Compared with systemic androgen deprivation therapy alone, the early (within 120 days of beginning ADT) addition of TBCT to ADT for newly diagnosed, metastatic, hormone‐sensitive prostate cancer prolonged both overall and disease‐specific survival and delayed disease progression. There was an increase in toxicity with TBCT in combination with ADT. There was also a small, clinically unimportant improvement in quality of life at 12 months with TBCT and ADT treatment.
The certainty of the evidence for time to death from any cause, risk of prostate cancer‐specific death and the time to disease progression was moderate. The certainty of the evidence was low for adverse events of all grades, people stopping treatment due to adverse events, and quality of life.
Of men diagnosed with prostate cancer, approximately 16% present with cancer that has spread at diagnosis. In addition, another 15% to 30% of men get the disease again after having primary treatment. Hormone therapy has been the first treatment for advanced cancer, but it does not cure it, and eventually the cancer comes back. Recently, studies have looked at whether chemotherapy, when given early, can improve outcomes.
Cochrane Systematic Review Sathianathen NJ et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Reviews, 2019, Issue 10. Art. No.: CD012816. DOI: 10.1002/14651858. CD012816.pub2. This review contains 3 studies involving 2261 participants.
Prostate cancer consultations are common in primary care and there is no one approach to testing and treatment that fits all patients. Urologist Simon van Rij discusses the key considerations and options for personalised care, appropriate investigation and treatment
![Amtech Medical marketing manager Jasmine Anderson and Ebos Health senior account manager Sageran Naidoo [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/2%28a%29.JPG?itok=Jdm5dZdg)
![Medtech CEO Geoffrey Sayer and MyPractice founder and Auckland-based specialist GP Ashwin Patel [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/3%28a%29.JPG?itok=LdPwyQwJ)
![Mahoe Medical Centre administration managers Ashlee Herbert and Julie-Ann Foreman [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/4%28b%29.JPG?itok=_NUoSaY2)
![Broadway Health Management Centre administrators Stef LeGros and Julie Johnson [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/5%28b%29.JPG?itok=Q5P9RMB1)
![Newtown Union Health Service administrators Tunisia Pohatu and Waty Arief-Macher [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/6%28a%29.JPG?itok=ttzKlXLf)
![SR Referrals client support staff Athulya Mohandas and Shona Cribb and support manager Amy Moyle [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/7%28a%29.JPG?itok=11zaUO5S)
![Webtools implementation specialist Hannah Laurie and head of marketing Bridget Holland [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/11%28b%29.JPG?itok=4Q_1zwTg)
![DataCraft Analytics operations manager Rachel Blanch and managing director Jayden Macrae [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/1%28c%29.JPG?itok=ipS4z2aa)
![Collaborative Aotearoa CEO Jess Morgan-French, Three Rivers Medical general manager Michelle Te Kira and Third Age Health chief executive Tony Wai [Image: NZD]](/sites/default/files/styles/thumbnail_cropped_100/public/2024-09/10%28a%29.JPG?itok=t2X4h7nC)
